Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Efficacy and Safety of Deep Sedation in Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma.

Sato K, Taniki N, Kanazawa R, Shimizu M, Ishii S, Ohama H, Takawa M, Nagamatsu H, Imai Y, Shiina S.

Adv Ther. 2019 Feb;36(2):344-354. doi: 10.1007/s12325-018-0865-z. Epub 2019 Jan 3.

PMID:
30607546
2.

Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery.

Wake T, Tateishi R, Nakagomi R, Fujiwara N, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Tanaka Y, Shiina S, Koike K.

Hepatol Res. 2018 Dec 20. doi: 10.1111/hepr.13302. [Epub ahead of print]

PMID:
30570810
3.

Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.

Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Shiina S, Koike K.

J Hepatol. 2019 Jan;70(1):78-86. doi: 10.1016/j.jhep.2018.09.029. Epub 2018 Oct 16.

PMID:
30336183
4.

Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation.

Uchino K, Tateishi R, Nakagomi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shibahara J, Shiina S, Koike K.

PLoS One. 2018 Jul 25;13(7):e0200943. doi: 10.1371/journal.pone.0200943. eCollection 2018.

5.

Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery.

Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y.

Can J Gastroenterol Hepatol. 2018 Jun 3;2018:4756147. doi: 10.1155/2018/4756147. eCollection 2018. Review.

6.

Pharmacological identification of β-adrenoceptor subtypes mediating isoprenaline-induced relaxation of guinea pig colonic longitudinal smooth muscle.

Chino D, Sone T, Yamazaki K, Tsuruoka Y, Yamagishi R, Shiina S, Obara K, Yamaki F, Higai K, Tanaka Y.

J Smooth Muscle Res. 2018;54(0):13-27. doi: 10.1540/jsmr.54.13.

7.

β-Adrenoceptor subtypes and cAMP role in adrenaline- and noradrenaline-induced relaxation in the rat thoracic aorta.

Shiina S, Kanemura A, Suzuki C, Yamaki F, Obara K, Chino D, Tanaka Y.

J Smooth Muscle Res. 2018;54(0):1-12. doi: 10.1540/jsmr.54.1.

8.

Size-Based Differentiation of Cancer and Normal Cells by a Particle Size Analyzer Assisted by a Cell-Recognition PC Software.

Shashni B, Ariyasu S, Takeda R, Suzuki T, Shiina S, Akimoto K, Maeda T, Aikawa N, Abe R, Osaki T, Itoh N, Aoki S.

Biol Pharm Bull. 2018 Apr 1;41(4):487-503. doi: 10.1248/bpb.b17-00776. Epub 2018 Jan 13.

9.

Successful local treatment for repeated hepatic recurrences of cholangiolocellular carcinoma: a report on a long-term survivor.

Shinohara K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Shimoyama Y, Shiina S, Tateishi R, Arano T, Nagino M.

Surg Case Rep. 2017 Dec 2;3(1):120. doi: 10.1186/s40792-017-0391-2.

10.

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A.

Neuro Oncol. 2018 Jan 10;20(1):66-77. doi: 10.1093/neuonc/nox132.

11.

Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.

Nozaki Y, Tamori S, Inada M, Katayama R, Nakane H, Minamishima O, Onodera Y, Abe M, Shiina S, Tamura K, Kodama D, Sato K, Hara Y, Abe R, Takasawa R, Yoshimori A, Shinomiya N, Tanuma SI, Akimoto K.

Genes Cancer. 2017 Jul;8(7-8):628-639. doi: 10.18632/genesandcancer.148.

12.

Impact of MUC1 Expression on the Progression of Intraductal Papillary Mucinous Neoplasm With Worrisome Features During Follow-up.

Tomishima K, Sai JK, Kanazawa R, Miura H, Shimizu R, Sato K, Ishii S, Saito H, Ito T, Fukumura Y, Shiina S, Watanabe S.

Pancreas. 2017 Oct;46(9):1127-1132. doi: 10.1097/MPA.0000000000000902.

PMID:
28902782
13.

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK.

Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Review.

14.

Hepatocellular Carcinoma: The Role of Interventional Oncology.

Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, Shiina S, Fontana A, Torzilli G.

Liver Cancer. 2016 Nov;6(1):34-43. Epub 2016 Nov 29. Review.

15.

Prior minimal endoscopic sphincterotomy to prevent pancreatitis related to endoscopic balloon sphincteroplasty.

Kanazawa R, Sai JK, Ito T, Miura H, Ishii S, Saito H, Tomishima K, Shimizu R, Sato K, Hayashi M, Watanabe S, Shiina S.

World J Gastrointest Endosc. 2016 Oct 16;8(18):663-668.

16.

Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study.

Okubo H, Kitamura T, Ando H, Fukada H, Igusa Y, Kokubu S, Miyazaki A, Fujimura A, Shiina S, Watanabe S.

J Clin Pharmacol. 2017 Mar;57(3):369-375. doi: 10.1002/jcph.811. Epub 2016 Sep 22.

PMID:
27530761
17.

The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.

Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shiina S, Koike K.

J Hepatol. 2016 Dec;65(6):1272-1273. doi: 10.1016/j.jhep.2016.07.043. Epub 2016 Aug 11. No abstract available.

PMID:
27524465
18.

Safety of immediate endoscopic sphincterotomy in acute suppurative cholangitis caused by choledocholithiasis.

Ito T, Sai JK, Okubo H, Saito H, Ishii S, Kanazawa R, Tomishima K, Watanabe S, Shiina S.

World J Gastrointest Endosc. 2016 Feb 10;8(3):180-5. doi: 10.4253/wjge.v8.i3.180.

19.

CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.

Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.

Cancer Immunol Res. 2016 Mar;4(3):259-68. doi: 10.1158/2326-6066.CIR-15-0060. Epub 2016 Jan 28.

20.

Absorption Kinetics of Subcutaneously Administered Ceftazidime in Hypoperfused Guinea Pigs.

Ebihara T, Oshima S, Okita M, Shiina S, Negishi A, Ohara K, Ohshima S, Iwasaki H, Yoneyama A, Kitazumi E, Kobayashi D.

Curr Ther Res Clin Exp. 2014 Nov 18;77:7-13. doi: 10.1016/j.curtheres.2014.09.006. eCollection 2015 Dec.

21.

Transdermal Dopamine Agonist Ameliorates Gastric Emptying in Parkinson's Disease.

Tateno H, Sakakibara R, Shiina S, Doi H, Tateno F, Sato M, Masaka T, Kishi M, Tsuyusaki Y, Aiba Y, Ogata T, Suzuki Y.

J Am Geriatr Soc. 2015 Nov;63(11):2416-8. doi: 10.1111/jgs.13800. No abstract available.

PMID:
26603068
22.

Levodopa Does Not Worsen Gastric Emptying in Parkinson's Disease.

Shiina S, Sakakibara R, Doi H, Tateno F, Sato M, Masaka T, Kishi M, Tsuyusaki Y, Ogata T, Aiba Y, Tateno H.

J Am Geriatr Soc. 2015 Oct;63(10):2185-6. doi: 10.1111/jgs.13675. No abstract available.

PMID:
26480981
23.

Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.

Kuramitsu S, Ohno M, Ohka F, Shiina S, Yamamichi A, Kato A, Tanahashi K, Motomura K, Kondo G, Kurimoto M, Senga T, Wakabayashi T, Natsume A.

Cancer Gene Ther. 2015 Oct;22(10):487-95. doi: 10.1038/cgt.2015.47. Epub 2015 Oct 9.

PMID:
26450624
24.

Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field.

Ito T, Nagahara A, Osada T, Kato J, Ueyama H, Saito H, Taniki N, Kanazawa R, Shimizu R, Sai J, Shiina S, Watanabe S.

Biomed Rep. 2015 Jul;3(4):457-460. Epub 2015 May 13.

25.

Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients.

Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Moriya K, Shiina S, Koike K.

Medicine (Baltimore). 2015 Jun;94(23):e901. doi: 10.1097/MD.0000000000000901.

26.

Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients.

Uchino K, Tateishi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Moriya K, Shiina S, Omata M, Koike K.

Hepatol Res. 2016 Apr;46(4):259-68. doi: 10.1111/hepr.12517. Epub 2015 May 15.

PMID:
25788045
27.

Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.

Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami T, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Tanaka Y, Ohtomo K, Shiina S, Koike K.

J Hepatol. 2015 Jul;63(1):131-40. doi: 10.1016/j.jhep.2015.02.031. Epub 2015 Feb 24.

28.

Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope.

Ikeda M, Yamaguchi M, Kato K, Nakamura K, Shiina S, Ichikawa-Ando T, Misaka H, Myojo K, Nakamura K, Sugimoto Y, Hamada H.

Biochem Biophys Res Commun. 2015 Mar 20;458(4):877-82. doi: 10.1016/j.bbrc.2015.02.051. Epub 2015 Feb 19.

PMID:
25701778
29.

Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma.

Minami T, Tateishi R, Shiina S, Nakagomi R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Koike K.

Hepatol Res. 2015 Oct;45(10):E99-E107. doi: 10.1111/hepr.12468. Epub 2015 Mar 3.

PMID:
25559860
30.

Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma.

Asaoka Y, Tateishi R, Nakagomi R, Kondo M, Fujiwara N, Minami T, Sato M, Uchino K, Enooku K, Nakagawa H, Kondo Y, Shiina S, Yoshida H, Koike K.

PLoS One. 2014 Nov 14;9(11):e111662. doi: 10.1371/journal.pone.0111662. eCollection 2014.

31.

Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients.

Nakagawa H, Fujiwara N, Tateishi R, Arano T, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Shiina S, Yoshida H, Koike K.

J Gastroenterol Hepatol. 2015 Feb;30(2):379-88. doi: 10.1111/jgh.12719.

PMID:
25168107
32.

Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma.

Fujiwara N, Tateishi R, Nakagawa H, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Shiina S, Yoshida H, Koike K.

Hepatol Res. 2015 Jun;45(6):645-55. doi: 10.1111/hepr.12398. Epub 2014 Sep 2.

PMID:
25070147
33.

Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation.

Fujiwara N, Tateishi R, Kondo M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Masuzaki R, Nakagawa H, Kondo Y, Asaoka Y, Shiina S, Yoshida H, Koike K.

Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1039-46. doi: 10.1097/MEG.0000000000000161.

PMID:
25051219
34.

Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography.

Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, Sato T, Nakagawa H, Masuzaki R, Asaoka Y, Kondo Y, Shiina S, Ikeda H, Omata M, Yoshida H, Koike K.

Hepatol Res. 2015 Apr;45(4):415-22. doi: 10.1111/hepr.12365. Epub 2014 Jun 19.

PMID:
24861870
35.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T.

Invest New Drugs. 2014 Oct;32(5):928-36. doi: 10.1007/s10637-014-0109-2. Epub 2014 May 15.

36.

Drastically reduced neoplastic seeding related to radiofrequency ablation for hepatocellular carcinoma.

Nakagomi R, Tateishi R, Shiina S, Imamura J, Fujiwara N, Asaoka Y, Kondo Y, Koike K.

Am J Gastroenterol. 2014 May;109(5):774-6. doi: 10.1038/ajg.2014.42. No abstract available.

PMID:
24797009
37.

An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

Kanai F, Obi S, Fujiyama S, Shiina S, Tamai H, Mochizuki H, Koike Y, Imamura J, Yamaguchi T, Saida I, Yokosuka O, Omata M.

Hepatol Int. 2014 Jan;8(1):94-103. doi: 10.1007/s12072-013-9459-7. Epub 2013 Jul 25.

PMID:
26202410
38.

Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan.

Sato A, Sata M, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T.

Intern Med. 2013;52(24):2701-6.

39.

Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K.

Hepatol Res. 2014 Oct;44(10):E137-44. doi: 10.1111/hepr.12258. Epub 2014 Jan 8.

PMID:
24125181
40.

Changes in risk of immediate adverse reactions to iodinated contrast media by repeated administrations in patients with hepatocellular carcinoma.

Fujiwara N, Tateishi R, Akahane M, Taguri M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Ohtomo K, Koike K.

PLoS One. 2013 Oct 2;8(10):e76018. doi: 10.1371/journal.pone.0076018. eCollection 2013. Erratum in: PLoS One. 2014;9(3):e93340. Uchino, Kouji [corrected to Uchino, Koji].

41.

Spontaneous clearance of serum hepatitis C virus RNA during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis C.

Minami T, Tateishi R, Shiina S, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Yoshida H, Koike K.

Hepatol Res. 2014 Oct;44(10):E32-7. doi: 10.1111/hepr.12203. Epub 2013 Aug 7.

PMID:
23841664
42.

IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K.

J Gastroenterol. 2014 Apr;49(4):748-54. doi: 10.1007/s00535-013-0826-x. Epub 2013 May 22.

PMID:
23689989
43.

CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial.

Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, Koike K.

Am J Gastroenterol. 2013 Aug;108(8):1305-13. doi: 10.1038/ajg.2013.109. Epub 2013 Apr 30.

44.

[Radiofrequency ablation for colorectal liver metastasis: 10-year outcome and future perspective].

Shiina S, Sato T, Kondo Y, Asaoka Y, Tateishi R, Koike K.

Nihon Geka Gakkai Zasshi. 2013 Mar;114(2):107-11. Japanese. No abstract available.

PMID:
23617193
45.

Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma.

Tateishi R, Shiina S, Akahane M, Sato J, Kondo Y, Masuzaki R, Nakagawa H, Asaoka Y, Goto T, Otomo K, Omata M, Yoshida H, Koike K.

PLoS One. 2013 Apr 12;8(4):e59040. doi: 10.1371/journal.pone.0059040. Print 2013.

46.

IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal.

Okushin K, Asaoka Y, Fukuda I, Fujiwara N, Minami T, Sato M, Mikami S, Uchino K, Enooku K, Kondo Y, Tateishi R, Goto T, Shiina S, Yoshida H, Koike K.

Case Rep Gastroenterol. 2012 Sep;6(3):784-9. doi: 10.1159/000346462. Epub 2012 Dec 22.

47.

Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience.

Mikami S, Tateishi R, Akahane M, Asaoka Y, Kondo Y, Goto T, Shiina S, Yoshida H, Koike K.

J Vasc Interv Radiol. 2012 Oct;23(10):1269-75. doi: 10.1016/j.jvir.2012.06.032.

PMID:
22999746
48.

Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors.

Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H, Omata M, Koike K.

Liver Int. 2012 Oct;32(9):1434-42. doi: 10.1111/j.1478-3231.2012.02838.x. Epub 2012 Jun 19.

49.

[Tumor markers for hepatocellular carcinoma].

Tateishi R, Enooku K, Shiina S, Koike K.

Nihon Rinsho. 2012 May;70(5):821-7. Review. Japanese.

PMID:
22620007
50.

Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence.

Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, Koike K, Yatomi Y, Ikeda H.

J Hepatol. 2012 Aug;57(2):330-6. doi: 10.1016/j.jhep.2012.03.012. Epub 2012 Apr 17.

PMID:
22521349

Supplemental Content

Loading ...
Support Center